$TRVI

Trevi Therapeutics Inc

  • NASDAQ
  • Pharmaceuticals: Major
  • Health Technology
  • Manufacturing
  • Medicinal and Botanical Manufacturing

PRICE

$3.96 ▲4.762%

Extented Hours

VOLUME

180,511

DAY RANGE

3.78 - 4.0983

52 WEEK

0.46 - 4.68

Join Discuss about TRVI with like-minded investors

profile
@singletary #StockTraders.NET
recently

👀 $imte $axsm $brcc $dbtx $trvi $aprn. daily's $amc $li $rcl $nio

44 Replies 7 👍 15 🔥

profile
@Chano #StockTraders.NET
recently

I traded $TRVI risking premarket with the thesis of the ATM but it was not cracking and opted out just to see my thesis working later

111 Replies 12 👍 15 🔥

profile
@dros #droscrew
recently

+Initiations 5/25: $ALGM $AMLX $CASY $GNRC $PHVS $POET $PRCH $SMRT $SQZ $TRMD $TRVI $WBX . -Initiations 5/25:

133 Replies 13 👍 11 🔥

profile
@TraderXx #StockTraders.NET
recently

$TRVI another pump, but coutious wiw this one

64 Replies 11 👍 9 🔥

Key Metrics

Market Cap

175.79 M

Beta

0.90

Avg. Volume

339.39 K

Shares Outstanding

42.77 M

Yield

0%

Public Float

0

Next Earnings Date

2022-11-10

Next Dividend Date

Company Information

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Trevi is also developing Haduvio for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease and is in the planning stages of a Phase 2 study in this indication. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.

Website:

HQ: ,

Related News